Author
@AponiaAnalytics AponiaAnalytics
grade Bx.com/AponiaAnalytics ↗
Numerate biotech catalyst analyst dissecting trial data, dilution, and insider flow
Publishes original, mechanism-aware analysis of biotech/phar
trader score
+4.91
hit rate
85%
mean α
+2.47%
signals 14d
54
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 85% hit rate, +2.47% mean alpha, trader score +4.91. Their last-14d mentions, direction-adjusted, have moved +2.5% since posting (mean over 20 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | · | @AponiaAnalytics | · | Summarizes mouse research on circadian vaccination timing and durable T-cell memory. | · | tweet ↗ |
| 2026-08-28 | · | @AponiaAnalytics | · | Describes preclinical PROTEXI results using antiviral memory to improve cancer vaccination. | · | tweet ↗ |
| 2026-08-28 | · | @AponiaAnalytics | · | Summarizes preclinical evidence that CARM1 blockade improves antitumor antigen presentation. | · | tweet ↗ |
| 2026-08-28 | MDSC | @AponiaAnalytics | +0.00 | Reviews metabolic reprogramming of suppressive myeloid cells as an oncology strategy. | · | tweet ↗ |
| 2026-08-28 | NWBO | @AponiaAnalytics | +0.05 | Reviews multi-part immunotherapy strategies for glioblastoma while stressing absent survival proof. | — | tweet ↗ |
| 2026-08-28 | NWBO | @AponiaAnalytics | +0.10 | Discusses coordinated immune activation and tumor-microenvironment remodeling in glioblastoma. | — | tweet ↗ |
| 2026-08-28 | · | @AponiaAnalytics | · | Summarizes early multi-omics research on therapeutically distinct macrophage states. | · | tweet ↗ |
| 2026-08-28 | · | @AponiaAnalytics | · | Explains T-cell exhaustion trajectories and consequences for checkpoint-drug development. | · | tweet ↗ |
| 2026-08-28 | · | @AponiaAnalytics | · | Reports early CAR-macrophage trial activity and limited efficacy in HER2-positive tumors. | · | tweet ↗ |
| 2026-08-27 | · | @AponiaAnalytics | · | Summarizes JAMA evidence that recent oncology approvals rely more on surrogate endpoints. | · | tweet ↗ |
| 2026-08-27 | ONC | @AponiaAnalytics | +0.35 | Reviews favorable zanidatamab combination survival data while emphasizing subgroup caveats. | · | tweet ↗ |
| 2026-08-27 | · | @AponiaAnalytics | · | Summarizes JAMA evidence that oncology approvals increasingly use surrogate endpoints. | · | tweet ↗ |
| 2026-08-27 | · | @AponiaAnalytics | · | Describes a testable mechanism of myeloid-mediated immunotherapy resistance in brain cancer. | · | tweet ↗ |
| 2026-08-27 | · | @AponiaAnalytics | · | Reports a preclinical triple-target ADC design with over fourfold higher payload internalization. | · | tweet ↗ |
| 2026-08-27 | · | @AponiaAnalytics | · | Summarizes a 62-patient study linking coagulation markers to CAR-T complications. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.